Novel Corona virus (COVID-19)
Corona contagions are positive sense single stranded RNA contagions that beget infection in nose, sinuses, or upper throat. It belongs to family of SARS and MERS. COVID-19 is the illness caused by SARS-COV-2, first outbreak does Wuhan megacity in China.
The pathogenesis of COVID-19 isn't defined but reports from numerous countries indicate that the contagion has the same medium by which it enters or invades host cells as SARS-COV. The origin of SARS-CoV-2 isn't well- established, still, it's established that batons are the fountainhead of affiliated contagions and that mortal to mortal transmission plays a critical part in its pathogenesis After entering into target cells following Shaft protein association with its receptor, viral RNA is reprised and polyadenylated, and encodes colorful structural andnon-structural polypeptide genes.
These polyproteins are adhered by proteases that parade chymotrypsin-suchlike exertion. Although transmembrane serine protease 2 (TMPRSS2) is the major protease associated with CoV activation and has been linked to SARS-CoV-2 activation, recent substantiation from single cell RNA-sequencing (scRNA-seq) analysis shows that ACE2 and TMPRSS2 aren't expressed in the same cell suggesting the involvement of other proteases similar as cathepsin B and L in this process.
In general, pattern recognition receptors (PRRs) fete overrunning pathogens including contagion’s. Contagions evoke several crucial host vulnerable responses similar as adding the release of seditious factors, induction and development of dendritic cells (DCs) and adding the conflation of type I interferons (IFNs), which are important in limiting viral spread. Both the ingrain and acquired vulnerable response is actuated by SARS-CoV-2. CD4 T cells stimulate B cells to produce contagion-specific antibodies including immunoglobulin (Ig) G and IgM and CD8 T cells directly kill contagion-infected cells. T coadjutor cells producer-inflammatory cytokines and intercessors to help the other vulnerable cells. SARS-CoV-2 can block the host vulnerable defense by suppressing T cell functions by converting their programmed cell deathe.g., by apoptosis. Likewise, the host product of complement factors similar as C3a and C5a and antibodies are critical in combating the viral infection.
Related Conference of Novel Corona virus (COVID-19)
11th World Congress and Exhibition on Antibiotics and Antibiotic Resistance
5th International conference on Vaccines, Vaccination and Immunization
Novel Corona virus (COVID-19) Conference Speakers
Recommended Sessions
- Diagnostic Immunology
- Haematopoietic, Lymphoid Malignancies and Immune System Development
- Immune System and Immunology
- Immunization and Vaccination
- Veterinary Allergology
- Allergy and Immunology
- Autoimmune Diseases and HIV
- Immune Disorder
- Immune Response Regulation
- Immunogenetics
- Immunoresearch and Immunotechnology
- Microbial Parasitic and Fungal Immunology
- Mucosal and regional Immunology
- Neonatal and Pediatric Immunology
- NeuroImmunology
- Novel Corona virus (COVID-19)
- OncoImmunology
- Stem Cells Immunology
- Technological Innovations in Immunology
- Therapeutic approaches to autoimmunity
- Thyroid Autoimmunity
- Transplantation and Computational Immunology
- Vaccines and Immunotherapy
- Veterinary and Comparative Immunology
- Viral Immunology
Related Journals
Are you interested in
- Antibiotic Prophylaxis - Antibiotics 2024 (UK)
- Antibiotic Resistance: Opportunities and Challenges - Antibiotics 2024 (UK)
- Antibiotic-resistant Bacterial infections - Antibiotics 2024 (UK)
- Antibiotics - Antibiotics 2024 (UK)
- Antibiotics for Various Diseases and Infections - Antibiotics 2024 (UK)
- Antibiotics: In Pregnancy and Lactation - Antibiotics 2024 (UK)
- Antimicrobial Peptides - Antibiotics 2024 (UK)
- Antimicrobial Therapy - Antibiotics 2024 (UK)
- Cancer Immunology and Immunotherapy - IMMUNOLOGY 2024 (Spain)
- Cell & Plant Biology - IMMUNOLOGY 2024 (Spain)
- Cell Biology - IMMUNOLOGY 2024 (Spain)
- CELL, ANIMAL & PLANT BIOLOGY - IMMUNOLOGY 2024 (Spain)
- Clinical Immunology & Current & Future Research - IMMUNOLOGY 2024 (Spain)
- Clinical Trials of Antibiotics - Antibiotics 2024 (UK)
- Current research in antibiotic resistance - Antibiotics 2024 (UK)
- Developing Alternatives to Antibiotics - Antibiotics 2024 (UK)
- Drug Discovery and Novel Delivery Technologies - Antibiotics 2024 (UK)
- Immune System - IMMUNOLOGY 2024 (Spain)
- Immuno informatics & Systems immunology - IMMUNOLOGY 2024 (Spain)
- Immuno-Genetics - IMMUNOLOGY 2024 (Spain)
- Immunogenetics - IMMUNOLOGY 2024 (Spain)
- Immunohistochemistry - IMMUNOLOGY 2024 (Spain)
- Immunology - IMMUNOLOGY 2024 (Spain)
- Immunology & Vaccines - Antibiotics 2024 (UK)
- Immunotherapy - IMMUNOLOGY 2024 (Spain)
- Infectious Diseases - Antibiotics 2024 (UK)
- Mechanism and Evolution of Antibiotic Resistance - Antibiotics 2024 (UK)
- Micro Organisms in Recent Drug Discovery - Antibiotics 2024 (UK)
- Microorganisms Producing Antibiotics - Antibiotics 2024 (UK)
- Modern Antibiotics for Various Diseases and Infections - Antibiotics 2024 (UK)
- New antibiotics and non-antibiotic approaches - Antibiotics 2024 (UK)
- Nutritional Immunology - IMMUNOLOGY 2024 (Spain)
- OncoImmunology - IMMUNOLOGY 2024 (Spain)
- Pediatric and Neonatal Immunology - IMMUNOLOGY 2024 (Spain)
- Pharmacokinetics and Pharmacodynamics of Antimicrobial Drugs - Antibiotics 2024 (UK)
- Pharmacology & Toxicology - Antibiotics 2024 (UK)
- Prevention and Control of Antibiotic Resistance - Antibiotics 2024 (UK)
- Reproductive Immunology - IMMUNOLOGY 2024 (Spain)
- The Next Generation Approach of Antibiotics - Antibiotics 2024 (UK)
- Transplantation and Computational Immunology - IMMUNOLOGY 2024 (Spain)
- Vaccines & Immunization - IMMUNOLOGY 2024 (Spain)
- Virology and infectious diseases - IMMUNOLOGY 2024 (Spain)